These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 7577481)
21. Treatment Patterns and Health Resource Utilization Among Patients Diagnosed With Early Stage Resected Non-Small Cell Lung Cancer at US Community Oncology Practices. Buck PO; Saverno KR; Miller PJ; Arondekar B; Walker MS Clin Lung Cancer; 2015 Nov; 16(6):486-95. PubMed ID: 25681298 [TBL] [Abstract][Full Text] [Related]
22. The cost of treating small cell lung cancer. Rosenthal MA; Webster PJ; Gebski VJ; Stuart-Harris RC; Langlands AO; Boyages J Med J Aust; 1992 May; 156(9):605-10. PubMed ID: 1320729 [TBL] [Abstract][Full Text] [Related]
23. Costs of non-small cell lung cancer in the Netherlands. van der Linden N; Bongers ML; Coupé VM; Smit EF; Groen HJ; Welling A; Schramel FM; Uyl-de Groot CA Lung Cancer; 2016 Jan; 91():79-88. PubMed ID: 26589654 [TBL] [Abstract][Full Text] [Related]
24. Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: A whole-disease model. Buja A; Rivera M; De Polo A; Brino ED; Marchetti M; Scioni M; Pasello G; Bortolami A; Rebba V; Schiavon M; Calabrese F; Mandoliti G; Baldo V; Conte P Thorac Cancer; 2021 Jan; 12(1):13-20. PubMed ID: 33219738 [TBL] [Abstract][Full Text] [Related]
25. Practical issues in the management of the patient with small cell lung cancer. Govindan R; Ihde DC Chest Surg Clin N Am; 1997 Feb; 7(1):167-81. PubMed ID: 9001763 [TBL] [Abstract][Full Text] [Related]
26. An estimate of the cost of conducting phase II trials in lung cancer. Evans WK; Dahrouge S; Stapleton J; Quinn C; Pollock D; Waterfield B; Lister D; Hansel F; Smith A Lung Cancer; 2000 May; 28(2):85-95. PubMed ID: 10717326 [TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness and lung cancer clinical trials. Du W; Reeves JH; Gadgeel S; Abrams J; Peters WP Cancer; 2003 Oct; 98(7):1491-6. PubMed ID: 14508837 [TBL] [Abstract][Full Text] [Related]
28. Lung cancer cure, care, and cost: let the data be your guide. Kris MG J Clin Oncol; 1997 Sep; 15(9):3027-9. PubMed ID: 9294464 [No Abstract] [Full Text] [Related]
29. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer. Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680 [TBL] [Abstract][Full Text] [Related]
30. Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601). Decroisette C; Monnet I; Berard H; Quere G; Le Caer H; Bota S; Audigier-Valette C; Geriniere L; Vernejoux JM; Chouaid C; J Thorac Oncol; 2011 Mar; 6(3):576-82. PubMed ID: 21270669 [TBL] [Abstract][Full Text] [Related]
31. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS). Andreas S; Chouaid C; Danson S; Siakpere O; Benjamin L; Ehness R; Dramard-Goasdoue MH; Barth J; Hoffmann H; Potter V; Barlesi F; Chirila C; Hollis K; Sweeney C; Price M; Wolowacz S; Kaye JA; Kontoudis I Lung Cancer; 2018 Oct; 124():298-309. PubMed ID: 29961557 [TBL] [Abstract][Full Text] [Related]
32. Hospitalization costs of lung cancer diagnosis in Turkey: Is there a difference between histological types and stages? Türk M; Yıldırım F; Yurdakul AS; Öztürk C Tuberk Toraks; 2016 Dec; 64(4):263-268. PubMed ID: 28393715 [TBL] [Abstract][Full Text] [Related]
33. Differences in practice patterns and costs between small cell and non-small cell lung cancer patients in Japan. Kuwabara K; Matsuda S; Fushimi K; Anan M; Ishikawa KB; Horiguchi H; Hayashida K; Fujimori K Tohoku J Exp Med; 2009 Jan; 217(1):29-35. PubMed ID: 19155605 [TBL] [Abstract][Full Text] [Related]
34. A comparison of the costs of paclitaxel and best supportive care in stage IV non-small-cell lung cancer. Earle CC; Evans WK Cancer Prev Control; 1997 Oct; 1(4):282-8. PubMed ID: 9765752 [TBL] [Abstract][Full Text] [Related]
35. Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer. Leighl NB; Shepherd FA; Kwong R; Burkes RL; Feld R; Goodwin PJ J Clin Oncol; 2002 Mar; 20(5):1344-52. PubMed ID: 11870178 [TBL] [Abstract][Full Text] [Related]
37. The cost of lung cancer in Turkey. Cakir Edis E; Karlikaya C Tuberk Toraks; 2007; 55(1):51-8. PubMed ID: 17401794 [TBL] [Abstract][Full Text] [Related]
38. The Role of Surgical Resection in Stage IIIA Non-Small Cell Lung Cancer: A Decision and Cost-Effectiveness Analysis. Samson P; Patel A; Robinson CG; Morgensztern D; Chang SH; Colditz GA; Waqar S; Crabtree TD; Krupnick AS; Kreisel D; Patterson GA; Meyers BF; Puri V Ann Thorac Surg; 2015 Dec; 100(6):2026-32; discussion 2032. PubMed ID: 26319488 [TBL] [Abstract][Full Text] [Related]
39. Cost and Survival Analysis Before and After Implementation of Dana-Farber Clinical Pathways for Patients With Stage IV Non-Small-Cell Lung Cancer. Jackman DM; Zhang Y; Dalby C; Nguyen T; Nagle J; Lydon CA; Rabin MS; McNiff KK; Fraile B; Jacobson JO J Oncol Pract; 2017 Apr; 13(4):e346-e352. PubMed ID: 28260402 [TBL] [Abstract][Full Text] [Related]